JPMorgan Chase & Co. has recruited Christopher Dass, a seasoned healthcare banker, from Deutsche Bank AG, a new addition to its team. 

Per BNN Bloomberg, Dass, who served as a managing director at Deutsche Bank, will assume the role of managing director at JPMorgan. He will be focusing on pharma-tech and pharma-services companies. 

READ NEXT: JPMorgan Q1 Profit Surpasses Expectations Despite Interest Income Missing Predictions

Christopher Dass' Role in JPMorgan Chase & Co.

Dass will join the bank's mid-cap investment banking group and report to John Richert. He will also collaborate closely with JPMorgan's North American healthcare services investment banking team, led by Nick Richitt, particularly on engagements involving larger companies. 

This move comes as JPMorgan integrates its commercial and investment banking segments, streamlining its operations under the leadership of Jennifer Piepszak and Troy Rohrbaugh. 

Dass brings a wealth of experience, having been an investment banker for about a decade and previously serving as an M&A lawyer. During his tenure at Deutsche Bank, he was pivotal in advising on various high-profile deals, including Norstella's merger with Citeline and Ciox Health LLC's merger with Datavant Inc.

JPMorgan and Deutsche Bank representatives have yet to comment on the news.

JPMorgan's expansion into the healthcare sector further diversifies its portfolio of ventures, following earlier reports from VCPost indicating its participation in an IPO led by the Carlyle Group for its IT and Outsourcing Company in India.

READ MORE: JPMorgan Asked By Carlyle Group to Help in the Initial Public Offering of its Company in India